Generate Biomedicines, Inc. GENB
Regular-session close
After hours · Nov 20, 4:46 PM ET
- YTD
- -24.58%
- 1 year
- -24.58%
5D -1.81 (-14.85%)
- Market cap
- 1.23B
- Revenue (ttm)
- 21.07M
- EPS (ttm)
- -2.49
- Shares out
- 129.10M
- Forward P/E
- -3.82
- YTD return
- -24.58%
- 1-year return
- -24.58%
- 50-day average
- 13.91
- 200-day average
- 13.95
- Volume
- 967.20K
- Avg volume
- 1.24M
- Open
- 10.06
- Previous close
- 10.37
- Day's range
- 9.40 – 10.58
- 52-week range
- 9.40 – 22.67
- Analysts
- Strong Buy
- Price target
- 26.80 (+180.9%)
- Earnings date
- Feb 11, 2027
Key statistics
- Enterprise value
- 1.01B
- Price / sales
- 58.45
- Price / book
- 3.23
- Revenue growth
- -56.20%
- Total cash
- 404.21M
- Total debt
- 75.34M
- Short % of float
- 12.03%
Fundamental scorecard
3 of 25 checks passed on GENB’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth No data
- Profitability No data
- Financial health 3 of 5
- Dividend No data
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 21.00
- Target (mean)
- 26.80
- Target (high)
- 30.00
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 11, 2027
Expected Feb 11, 2027. Consensus EPS estimate -0.684.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2027 | Dec 30, 2026 | -0.70667 | — | — | — |
| Nov 12, 2026 | Sep 30, 2026 | -0.55667 | -0.68 | -0.12 | -22.15% |
| Aug 6, 2026 | Jun 30, 2026 | -0.50833 | -0.52 | -0.01 | -2.30% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Oct 5, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 8, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 28, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| May 14, 2026 | Morgan Stanley | main | Overweight | Overweight |
| May 8, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Generate Biomedicines, Inc.
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- generatebiomedicines.com
News
Your note
Sign in to keep a note on GENB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AFEYAN NOUBAR BOGHOS | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Mar 1, 2026 | 0 |
| ARNOLD FRANCES H PH.D. | Director | Sale | Oct 28, 2026 | 452,535 |
| BANCEL STEPHANE J | Director | Conversion of Exercise of derivative security | Mar 1, 2026 | 0 |
| GROUS BETH | Officer | Purchase | Mar 1, 2026 | 0 |
| MENDILLO JANE L. | Director | Purchase | Mar 1, 2026 | 1,500 |
| NALLY MICHAEL | Chief Executive Officer | Purchase | Mar 3, 2026 | 2,889,150 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Flagship Pioneering LLC | 48.55% | 62,673,117 | 597.90M | Sep 29, 2026 |
| FMR, LLC | 5.57% | 7,186,203 | 68.56M | Sep 29, 2026 |
| Capital World Investors | 3.25% | 4,201,990 | 40.09M | Sep 29, 2026 |
| Braidwell LP | 2.29% | 2,962,249 | 28.26M | Sep 29, 2026 |
| JPMORGAN CHASE & CO | 2.06% | 2,654,810 | 25.33M | Sep 29, 2026 |
| Deep Track Capital, Lp | 1.94% | 2,507,449 | 23.92M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 2.91% | 3,752,630 | 35.80M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.91% | 2,462,992 | 23.50M | Sep 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 1.26% | 1,628,671 | 15.54M | Oct 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 0.63% | 816,876 | 7.79M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.59% | 763,690 | 7.29M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.49% | 636,804 | 6.08M | Sep 29, 2026 |
